Exact Sciences Lab and OncoExTra test selected by NCI for ComboMATCH clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI has selected Exact Sciences Corp.’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, an NCI-funded precision medicine initiative. As a ComboMATCH-designated lab, Exact Sciences will use its new OncoExTra test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient’s tumor that may be most effective to treat. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
Fifty-four years ago, in his State of the Union Message in January 1971, President Nixon proposed a visionary and vigorous new challenge.  He said “The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon” should be applied to finding a cure for cancer.  He followed up by requesting an appropriation of $100 million, and the promise to ask for whatever additional funds could be effectively used.  

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login